What’s the current market cap for Grifols stock?

Grifols (GRFS) has a market cap of $6.3bn as of June 23, 2026.

What is the P/E ratio for Grifols stock?

The price to earnings (P/E) ratio for Grifols (GRFS) stock is 10.45 as of June 23, 2026.

Does Grifols stock pay dividends?

Yes, the Grifols (GRFS) stock pays dividends to shareholders. As of June 23, 2026, the dividend rate is $0.14238 and the yield is 1.96%. Grifols has a payout ratio of 30.84% on a trailing twelve-month basis.

When is the next Grifols dividend payment date?

The next Grifols (GRFS) dividend payment date is unconfirmed.

What is the beta indicator for Grifols?

Grifols (GRFS) has a beta rating of 1.17. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy Grifols stock | $GRFS Share Price

13:30

15:10

16:45

18:25

20:00

About Grifols

Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.

Ticker

$GRFS

Sector

Health

Primary listing

NASDAQ

Employees

25,000

Headquarters

Barcelona, Spain

Website

www.grifols.com

Grifols Metrics

BasicAdvanced

$6.3bn

10.45

$0.70

1.17

$0.14

1.96%

What the Analysts think about Grifols

Analyst ratings (Buy, Hold, Sell) for Grifols stock.

Bulls say / Bears say

Grifols’ board approved a U.S. IPO for up to 20% of its Biopharma subsidiary, aiming to raise fresh capital to reduce debt and unlock valuation in its largest division (Reuters).

Free cash flow jumped to €468 million in FY 2025 (pre-M&A/pre-dividends), rising by over €200 million year-on-year, and management guided 2026 cash‐generation to €500–575 million, underpinning stronger leverage and investment capacity (MarketBeat).

Grifols plans a U.S. fibrinogen launch in Q2 2026 with up to €800 million market potential, enhancing its Biopharma portfolio diversification and supporting future top-line growth (MarketBeat).

Grifols faces restrictions on its Canadian plasma-collection licence after Health Canada deemed multiple centres unsafe following donor-related incidents, which may tighten its North American plasma supply and raise compliance costs (Bloomberg).

The Diagnostic segment’s revenues fell 9.6% year-on-year in Q1 2026 as Grifols normalised inventories and absorbed currency headwinds, weighing on overall sales mix and segment margins (Investing.com).

Grifols’ Bio Supplies business plunged 33.5% in Q1 2026 due to the unwinding of prior contract distributions, highlighting volatility in its non-therapeutic plasma products segment (Investing.com).

Data summarised monthly by Lightyear AI. Last updated on 2 Jun 2026.

Grifols Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

Grifols Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Bulls say / Bears say

Grifols’ board approved a U.S. IPO for up to 20% of its Biopharma subsidiary, aiming to raise fresh capital to reduce debt and unlock valuation in its largest division (Reuters).

Grifols plans a U.S. fibrinogen launch in Q2 2026 with up to €800 million market potential, enhancing its Biopharma portfolio diversification and supporting future top-line growth (MarketBeat).

Grifols’ Bio Supplies business plunged 33.5% in Q1 2026 due to the unwinding of prior contract distributions, highlighting volatility in its non-therapeutic plasma products segment (Investing.com).

Data summarised monthly by Lightyear AI. Last updated on 2 Jun 2026.

About Grifols

Ticker

Employees

Grifols Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about Grifols

Analyst Ratings

Bulls say / Bears say

Grifols Financial Performance

Income Statement

Grifols Earnings Performance

Earnings per share (EPS)

Grifols News

Grifols approves IPO of its US biopharma business

Buy $GRFS

Lightyear

Legal

Work with us

Bulls say / Bears say

Grifols/$GRFS

About Grifols

Ticker

Employees

Grifols Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about Grifols

Analyst Ratings

Bulls say / Bears say

Grifols Financial Performance

Income Statement

Grifols Earnings Performance

Earnings per share (EPS)

Grifols News

Grifols approves IPO of its US biopharma business

What’s the current market cap for Grifols stock?

What is the P/E ratio for Grifols stock?

Does Grifols stock pay dividends?

When is the next Grifols dividend payment date?

What is the beta indicator for Grifols?

Bulls say / Bears say